World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
74
Citations
21271
World Ranking
1223
National Ranking
19

Peter Atadja publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Peter Atadja sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 227 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Peter Atadja D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Atadja sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 74 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

Peter Atadja is affiliated with Novartis in Switzerland and conducts research primarily within the fields of Biochemistry, Genetics and Molecular Biology, as well as Medicine. Their work spans several subfields, most notably Molecular Biology, Hematology, Oncology, Cell Biology, and Sociology and Political Science.

The main topics addressed in their research include:

  • Epigenetics and DNA Methylation
  • Protein Degradation and Inhibitors
  • Cancer-related gene regulation
  • Acute Myeloid Leukemia Research
  • RNA modifications and cancer
  • Peptidase Inhibition and Analysis
  • RNA Interference and Gene Delivery

Atadja has published multiple papers across several peer-reviewed journals. Notable recent publications include:

  • "Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies" (2022) in the Journal of Medicinal Chemistry
  • "Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction" (2023) in ACS Chemical Biology
  • "Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets" (2022) in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  • "Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia" (2020) in Clinical Epigenetics
  • "Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells" (2020) in Clinical Cancer Research

The frequent publication venues where Atadja's work appears include:

  • Clinical Cancer Research
  • Journal of Medicinal Chemistry
  • ACS Chemical Biology
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  • Clinical Epigenetics

The scientist collaborates regularly with a group of coauthors, including:

  • Kehao Zhao
  • Zhengtian Yu
  • Mengxi Zhao
  • En Li
  • Guo Li

Best Publications

  • High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

    Hui Gao;Joshua M Korn;Stéphane Ferretti;John E Monahan

  • Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

    Purva Bali;Michael Pranpat;James Bradner;Maria Balasis

  • Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

    Unknown

  • Epigenetics in cancer: Targeting chromatin modifications

    Leigh Ellis;Peter W. Atadja;Ricky W. Johnstone

  • The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

    Alejandro Villagra;Fengdong Cheng;Hong Wei Wang;Ildelfonso Suarez

  • Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

    Unknown

  • Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

    Prince George;Purva Bali;Srinivas Annavarapu;Anna Scuto

  • Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells

    Ramadevi Nimmanapalli;Lianne Fuino;Purva Bali;Maura Gasparetto

  • Increased activity of p53 in senescing fibroblasts

    Peter Atadja;Howard Wong;Igor Garkavtsev;Claude Veillette

  • Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

    Warren Fiskus;Yongchao Wang;Arun Sreekumar;Kathleen M. Buckley

  • Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

    Lianne Fuino;Purva Bali;Sylvie Wittmann;Sreenivasa Donapaty

  • Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

    Fang Cao;Elizabeth C. Townsend;Hacer Karatas;Jing Xu

  • The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

    Patricia Maiso;Xonia Carvajal-Vergara;Enrique M. Ocio;Ricardo López-Pérez

  • Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

    Fei Guo;Celia Sigua;Jianguo Tao;Purva Bali

  • Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion

    Yonghua Yang;Rehka Rao;Jie Shen;Yun Tang

  • NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

    Laurence Catley;Ellen Weisberg;Yu-Tzu Tai;Peter Atadja

  • HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

    Rekha Rao;Warren C Fiskus;Yonghua Yang;Pearl Lee

  • Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

    Yongchao Wang;Warren Fiskus;Daniel G. Chong;Kathleen M. Buckley

  • Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy

    Yonghua Yang;Warren Fiskus;Bao Yong;Peter Atadja

  • N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).

    Unknown

Frequent Co-Authors

Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center
Ricky W. Johnstone
Ricky W. Johnstone Peter MacCallum Cancer Centre
Karin Vanderkerken
Karin Vanderkerken Vrije Universiteit Brussel
Roberto Pili
Roberto Pili University at Buffalo, State University of New York
Karl Riabowol
Karl Riabowol University of Calgary
Amita Patnaik
Amita Patnaik University of Chicago
Jie Wu
Jie Wu Temple University
Ellen Weisberg
Ellen Weisberg Harvard University
Masoud Vedadi
Masoud Vedadi Structural Genomics Consortium
Cheryl H. Arrowsmith
Cheryl H. Arrowsmith Structural Genomics Consortium

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Molecular Biology opens the door to a wide range of online degrees and career opportunities. For students with a background in nursing, there are bsn to msn bridge programs that can help advance careers in healthcare and laboratory sciences, complementing skills in molecular techniques.

If you’re exploring academic options beyond traditional universities, consider enrolling in non profit online schools. These institutions often provide accredited, affordable, and flexible degree paths in science and related fields—ideal for working professionals or those seeking quality distance education.

For active-duty service members or veterans interested in the life sciences, there are online colleges for military. These schools offer military-friendly policies and support services to help you transition smoothly into a molecular biology career.

Additionally, students interested in integrating social impact with science may explore online msw programs. Social work professionals with a science background are in demand for roles in healthcare, public health, and community outreach.

Best Scientists Citing Peter Atadja

Trending Scientists

Recently Published Articles